Cetuximab versus methotrexate in first-line treatment of older, frail patients with inoperable recurrent or metastatic head and neck cancer (ELAN UNFIT): a randomised, open-label, phase 3 trial-Reference-Cited by-同舟云学术

Cetuximab versus methotrexate in first-line treatment of older, frail patients with inoperable recurrent or metastatic head and neck cancer (ELAN UNFIT): a randomised, open-label, phase 3 trial

Published:2024-03 Issue:3 Volume:5 Page:e182-e193
ISSN:2666-7568
Container-title:The Lancet Healthy Longevity
language:en
Short-container-title:The Lancet Healthy Longevity

Author:

Guigay Joël,Ortholan Cécile,Vansteene Damien,Cupissol Didier,Even Caroline,Kaminsky Marie-Christine,Sire Christian,Blot Emmanuel,Debourdeau Philippe,Bozec Laurence,Saada-Bouzid Esma,Fayette Jérôme,Dalloz Pierre,Pointreau Yoann,Caer Hervé Le,Falandry Claire,Digue Laurence,Braccini Antoine,Lopez Stéphane,Guillet Pierre,Michel Cécile,Cheurfa Nadir,Schwob Dominique,Bourhis Jean,Mertens Cécile,Aupérin Anne

Publisher

Elsevier BV

Reference27 articles.

1. Association of patient comorbid conditions with cancer clinical trial participation;Unger;JAMA Oncol,2019

2. Inclusion of elderly patients in oncology clinical trials;Le Saux;Ann Oncol,2016

3. Participation of patients 65 years of age or older in cancer clinical trials;Lewis;J Clin Oncol,2003

4. Decision making in older adults with cancer;DuMontier;J Clin Oncol,2021

5. Current treatment options for recurrent or metastatic head and neck squamous cell carcinoma;Sacco;J Clin Oncol,2015

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Kopf-Hals-Onkologie des älteren Patienten;Die MKG-Chirurgie;2024-07-30

2. Adapted EXTREME regimen in the first-line treatment of fit, older patients with recurrent or metastatic head and neck squamous cell carcinoma (ELAN-FIT): a multicentre, single-arm, phase 2 trial;The Lancet Healthy Longevity;2024-06

3. Is systemic anticancer treatment suitable for older patients?;The Lancet Healthy Longevity;2024-03

4. Synergistic Potential of Methotrexate and Gefitinib: A Promising Palliative Approach for Advanced and Recurrent Head and Neck Cancers;JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH;2024